The efficacy of abraxane on osteosarcoma xenografts in nude mice and expression of secreted protein, acidic and rich in cysteine

American Journal of the Medical Sciences

Volumn 344, Issue 3, 2012, Pages 199-205

  Yang, Yongkun ^a   Niu, Xiaohui ^a   Zhang, Qing ^a   Hao, Lin ^a   Ding, Yi ^a   Xu, Hairong ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; OSTEONECTIN; PACLITAXEL; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; OSTEOSARCOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 84865698197     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31823e62e5     Document Type: Article

References (37)

1. Dahlin D.C. Coventry MB. Osteogenic sarcoma. A study of six hundred cases J. Bone Joint Surg Am 49 1967 101 110
2. Jaffe N. Recent advances in the chemotherapy of metastatic osteogenic sarcoma Cancer 30 1972 621 627
3. Cores E.P. Holland J.F. Wang J.J. Doxorubicin in disseminated osteosarcoma JAMA 221 1972 1132 1138
4. Rosen G. Suwansirikul S. Kwon C. High-dose methotrexate with citrovorum factor rescue, and adriamycin in childhood osteogenic sarcoma Cancer 33 1974 1151 1163
5. Meyers P.A. Schwartz C.L. Krailo M.D. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children’s Oncology Group J Clin Oncol 26 2008 633 638
6. Bielack S. Kempf-Bielack B. Winkler K. Osteosarcoma: relationship of response to preoperative chemotherapy and type of surgery to local recurrence J Clin Oncol 14 1996 683 684
7. Lewis I.J. Nooij M.A. Whelan J. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup J Natl Cancer Inst 99 2007 112 118
8. Serra M. Reverter-Branchat G. Maurici D. Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells Ann Oncol 15 2004 151 160
9. Schwartz C.L. Gorlick R. Teot L. Children’s Oncology Group. Multiple drug resistance in osteogenic sarcoma: INTO133 from the Children’s Oncology Group J Clin Oncol 25 2007 2057 2062
10. Patel S.R. Papadopoulos N.E. Player C. Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variants Cancer 78 1996 741 744
11. Tiruppathi C. Finnegan A. Malik A.B. Isolation and characterization of a cell surface albumin-binding protein from vascular endothelial cells Proc Natl Acad Sci USA 93 1996 250 254
12. Schnitzer J. Oh P. Antibodies to SPARC inhibit albumin binding to SPARC, gp60, and microvascular endothelium Am J Physiol 263 H 1992 1872 1879
13. Gradishar W.J. Tjulandin S. Davidson N. Superior efficacy of nanoparticle albumin-bound paclitaxel (Abraxane, ABI-007) compared with polyethlyated castor oilbased paclitaxel (Taxol) in women with metastatic breast cancer: results of a phase III trial J Clin Oncol 23 2005 7794 7803
14. Wong F.H. Huang C.Y. Su L.J. Combination of microarray profiling and protein-protein interaction databases delineates the minimal discriminators as a metastasis network for esophageal squamous cell carcinoma Int Oncol 34 2009 117 128
15. Kumar S. WeaverMechanics, malignancy V, and metastasis: the force journey of a tumor cell Cancer Metastasis Rev 28 2009 113 127
16. Brekken R.A. Puolakkainen P. Graves D.C. Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM J Clin Invest 111 2003 487 495
17. Desai N. Trieu V. Damascelli B. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients Transl Oncol 2 2009 59 64
18. Trieu V. Damascelli B. Soon-Shiong P. SPARC expression in head and neck cancer correlates with tumor response to nanoparticle albumin-bound paclitaxel (nab-paclitaxel, ABI-007, Abraxane) Proc Am Assoc Cancer Res 47 2006 1050 l
19. Tomayko M.M. Reynolds C.P. Determination of subcutaneous tumor size in athymic (nude) mice Cancer Chemother Pharmacol 24 1989 148 154
20. Maysa A.-K. Vinni J.N. Chung Gina G. Long-term assessment of cardiac function after dose-dense and intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer Breast Cancer Res Treat 104 2007 341
21. Arie K. Ilan G. Carmit M. Peripartum cardiomyopathy occur ring in a patient previously treated with doxorubicin Am J Med Sci 314 1997 399 400
22. Johansen P.B. Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse Cancer Chemother Pharmacol 5 1981 267 270
23. Lu K. Lue K. Chou M. Paclitaxel induces apoptosis via caspase-3 activation in human osteogenic sarcoma cells (U-2 OS) J Orth Res 23 2005 988 994
24. McClung H.M. Thomas S.L. Osenkowsld P. SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells Neurosci Lett 419 2007 172 177
25. Demaria S. Volm M.D. Shapiro R.L. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy Clin Cancer Res 7 2001 3025 3030
26. Markman M. Rowinsky E. Hakes T. Phase I trial of intraperitoneal Taxol: a Gynecologic Oncology Group Study J Clin Oncol 10 1992 1485 1491
27. Gian V.G. Johnson T.J. Marsh R.W. A phase II trial of paclitaxel in the treatment of recurrent or metastatic soft tissue sarcomas or bone sarcomas J Exp Ther Oncol l 1996 186 190
28. Fan W. Everett E.T. Tang C. Glucocorticoids-mediated inhibi tion of paclitaxel-induced apoptosis in leiomyosarcoma cells Cell Pharmacol 1 1994 205 212
29. Fonseca C. Simoes S. Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity J Control Release 83 2002 273 286
30. Huisman M.T. Chhatta A.A. van Tellingen O. MRP2(ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid Int J Cancer 116 2005 824 829
31. Desai N. Trieu V. Yao Z. Increased antitumor activity, intratumor paclitaxel concentrations and endothelial cell transport if cremaphor-free, albumin-bound paclitaxel, ABI-007, compared with cremaphor-based paclitaxel Clin Cancer Res 12 2006 1317 1324
32. Desai N. Trieu V. Larn Y.H. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status Anticancer Drugs 19 2008 899 909
33. Porter P.L. Sage E.H. Lane T.F. Distribution of SPARC in normal and neoplastic human tissue J Histochem Cytochem 43 1995 791 800
34. Seno T. Harada H. Kohno S. Down-regulation of SPARC expression inhibits cell migration and invasion in malignant gliomas Int J Oncol 34 2009 707 715
35. Helleman J. Jansen M.P.H.M. Ruigrok-Ritstier K. Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response Clin Cancer Res 14 2008 5555 5564
36. Fanburg-Smith J. Bratthauer G.L. Miettinen M. Osteocalcin and osteonectin immunoreactivity in extraskeletal osteosarcoma: a study of 28 cases Hum Pathol 30 1999 32 38
37. Sparreboom A. Scripture C.D. Trieu V. Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle albu min-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol) Clin Cancer Res l1 2005 4136 4143